share_log

復星醫藥：董事會會議日期

FOSUN PHARMA: DATE OF BOARD MEETING

Hong Kong Stock Exchange ·  Apr 17 04:47
Summary by Moomoo AI
上海復星醫藥（集團）股份有限公司（「復星醫藥」）將於2024年4月29日（星期一）召開董事會會議，屆時將考慮及通過該公司及其附屬公司截至2024年3月31日止三個月的第一季度業績。復星醫藥的執行董事包括吳以芳先生、王可心先生、關曉暉女士及文德鏞先生，非執行董事為陳啟宇先生、姚方先生、徐曉亮先生及潘東輝先生，獨立非執行董事則包括李玲女士、湯谷良先生、王全弟先生及余梓山先生。會議的主要目的是審核和發布第一季度的財務成績。
上海復星醫藥（集團）股份有限公司（「復星醫藥」）將於2024年4月29日（星期一）召開董事會會議，屆時將考慮及通過該公司及其附屬公司截至2024年3月31日止三個月的第一季度業績。復星醫藥的執行董事包括吳以芳先生、王可心先生、關曉暉女士及文德鏞先生，非執行董事為陳啟宇先生、姚方先生、徐曉亮先生及潘東輝先生，獨立非執行董事則包括李玲女士、湯谷良先生、王全弟先生及余梓山先生。會議的主要目的是審核和發布第一季度的財務成績。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD A BOARD MEETING ON MONDAY, APRIL 29, 2024, AT WHICH TIME THE COMPANY AND ITS SUBSIDIARIES WILL CONSIDER AND APPROVE THE FIRST QUARTERLY RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2024. The Executive Directors of Fuxing Pharmaceuticals include Mr. Wu Yifang, Mr. Wang Ke Chin, Ms. Guan Xiaofui and Mr. Wen De Yung. The Non-Executive Directors are Mr. Chan Kai Yu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Tung Fai. The Independent Non-Executive Directors include Ms. Li Ling, Mr. Yuan-Leung, Mr. Wang Quan and Mr. Yu Zi Shan Raw. The primary purpose of the meeting is to review and release the financial results for the first quarter.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD A BOARD MEETING ON MONDAY, APRIL 29, 2024, AT WHICH TIME THE COMPANY AND ITS SUBSIDIARIES WILL CONSIDER AND APPROVE THE FIRST QUARTERLY RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2024. The Executive Directors of Fuxing Pharmaceuticals include Mr. Wu Yifang, Mr. Wang Ke Chin, Ms. Guan Xiaofui and Mr. Wen De Yung. The Non-Executive Directors are Mr. Chan Kai Yu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Tung Fai. The Independent Non-Executive Directors include Ms. Li Ling, Mr. Yuan-Leung, Mr. Wang Quan and Mr. Yu Zi Shan Raw. The primary purpose of the meeting is to review and release the financial results for the first quarter.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more